Uncategorized
This week in Drug Discovery (30 March – 3 April)
News round-up for 30 March – 3 April by Diana Turner, Deputy Editor, DDW.
This week, there have been a number of developments in neuroscience drug discovery. Elsewhere, a new treatment for platinum-resistant epithelial ovarian cancer has been approved in the US.
The top stories:
FDA approves Denali’s Hunter syndrome treatment
The US Food and Drug Administration (FDA) has granted accelerated approval for Avlayah (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier.
Lilly acquires sleep-wake disorders specialist Centessa
Eli Lilly has announced a definitive agreement under which it will acquire Centessa Pharmaceuticals for approximately $6.3 billion upfront and a potential equity value of $1.5 billion.
AI-powered ‘co-scientist’ wins prestigious Alzheimer’s prize
Developers of an AI-powered ‘co-scientist’ have been awarded the $1 million Alzheimer’s Insights AI Prize.
Global initiative to tackle gaps in ALS/MND drug discovery
A global initiative has launched to close the gap in ALS/MND drug discovery.
Platinum-resistant ovarian cancer drug gets FDA green light
The US Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The post This week in Drug Discovery (30 March – 3 April) appeared first on Drug Discovery World (DDW).